Strengthening pharmacotherapy research for COVID-19-induced pulmonary fibrosis

Table 1 The recommended dosages in literatures for some medications in use

Medications	Recommended dosages
Pirfenidone	2400 mg/d for 12-24 wk[6]
Nintedanib	150 mg or 100 mg (for patients with mild hepatic impairment) twice daily[10]
N-acetylcysteine	Oral 600 mg every 8 h, oral 600 mg twice daily for 14 d, or intravenous 40 mg/(kg × d) for 3 d[16]
Anakinra	A total dose of 600 mg (a loading dose of 200 mg twice daily, followed by 100 mg once daily for 2 d)[19]
Nimotuzumab	Intravenous administration: 2-3 times with an interval of 72 h, including a loading dose of 200 mg, followed by 100 mg[21]
Vitamin D	COVID-19 patients with 25-hydrodroxyvitamin D serum levels under 20 ng/mL: 6000-7000 oral IU/d for the first 6-8 wk for correction of deficiency and 2000 to 3000 oral IU/d for maintenance[22]

COVID-19: Coronavirus disease 2019.